Nacif v. Athira Pharma Inc

District Court, W.D. Washington·Decided February 15, 2024·No. 2:21-cv-00861·Unknown

Opinion

UNITED STATES DISTRICT COURT WESTERN DISTRICT OF WASHINGTON AT SEATTLE ANTONIO BACHAALANI NACIF; WIES RAFI; and HANG GAO, individually and on behalf of all others similarly situated, Plaintiffs, C21-0861 TSZ v. ATHIRA PHARMA, INC.; and LEEN KAWAS, Ph.D., Defendants.

THIS MATTER comes before the Court on plaintiffs’ unopposed renewed motion for preliminary approval of a proposed class settlement, docket no. 125. By Order entered September 27, 2023, docket no. 123, the Court denied plaintiffs’ previous motion, docket no. 118, for preliminary approval of a proposed class settlement because (i) an intraclass conflict of interest existed, and (ii) the proposed settlement could not be certified as “treat[ing] class members equitably relative to each other.” Order at 5–9 (docket no. 123) (quoting Fed. R. Civ. P. 23(e)(2)(D)). The parties have since engaged in further settlement negotiations and have entered into an Amended Stipulation and Agreement of Settlement (“Settlement Agreement”), docket no. 125-2. Having reviewed the Settlement Agreement, the pending motion, and the other materials submitted by the parties, the Court enters the following Order granting the motion in part, preliminarily approving the proposed settlement, certifying a class and two subclasses, deferring in part as to the proposed notices and claim form, requiring submission of an opt-out (exclusion Discussion As indicated in the Court’s earlier Order, this case involves publicly traded

common stock of defendant Athira Pharma, Inc. (“Athira”), some of which was acquired in connection with Athira’s initial public offering (“IPO”) in September 2020, some of which was purchased when Athira conducted a secondary public offering (“SPO”) in January 2021, and some of which cannot be traced to either the IPO or the SPO. In response to the Court’s inquiries, see Order at 11–12 (docket no. 123); Minute Order at ¶ 1(a)(i) (docket no. 119), the parties have clarified that all Athira shares issued before

the IPO (and SPO) were subject to lock-up or market-stand-off restrictions that prevented their trading until the market opened on March 17, 2021. See Duncan Decl. at ¶¶ 3–8 (docket no. 125-7). Based on this information, the parties have substantially simplified their traceability analysis for purposes of the claims in this litigation, which are now as follows:

Securities Act Claims: Claims relating to Athira’s publicly traded common stock acquired during the period from September 17, 2020, through March 16, 2021; such claims are brought pursuant to Sections 11, 12(a)(2), and 15 of the Securities Act of 1933 (“Securities Act”), 15 U.S.C. §§ 77k, 77l, and 77o; and Exchange Act Claims: Claims relating to Athira’s publicly traded common stock acquired during the period from March 17, 2021, through June 17, 2021; such claims were asserted under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (“Exchange Act”), 15 U.S.C. §§ 78j(b) & 78t(a), and United States Securities and Exchange Commission (“SEC”) Rule 10b-5, 17 C.F.R. § 240.10b-5. See Pl.’s Renewed Mot. at 5–6 (docket no. 125); see also Am. Compl. (docket no. 74). In other words, the Securities Act Claims relate to Athira shares traceable to the IPO and SPO, and the Exchange Act Claims concern Athira shares purchased after the lock-up period expired and before “corrective information” was disclosed. See Nye Decl. at ¶ 8 (docket no. 125-5); see also Am. Compl. at ¶ 91 (docket no. 74) (quoting a press release

issued by Athira after the market closed on June 17, 2021). A. Joinder In addition to involving separate timeframes, the two types of claims in this matter differ with regard to their litigation status. Although some portions of the Securities Act Claims remain viable, the Exchange Act Claims have been dismissed, see Order (docket no. 89), and they have not been repleaded by the lead plaintiffs, Antonio Bachaalani

Nacif and Wies Rafi. See Order at 2–4 (docket no. 123) (reciting the procedural history of these claims and observing that the “decision not to timely amend [the] operative pleading renders ‘final’ the earlier dismissal without prejudice” (quoting Order at 5 (docket no. 114))). As a result, Nacif’s and Rafi’s positions are not “typical” of those of the absent class members. See Order at 5–7 (docket no. 123) (citing Epstein v. MCA,

Inc., 179 F.3d 641, 652–53 (9th Cir. 1999) (Thomas, C.J., dissenting)); see also Fed. R. Civ. P. 23(a)(3) & (e)(2)(A). To cure this inherent conflict of interest, the parties propose to add Hang Gao as a named plaintiff. See Stlm’t Agr. at ¶ 1(hh) (docket no. 125-2 at 13). Gao’s attorneys participated in a mediation session conducted on November 16, 2023, and signed the Settlement Agreement on Gao’s behalf. See Melnick Decl. at 1 n.1

& ¶ 11 (docket no. 125-4); Stlm’t Agr. at 40 (docket no. 125-2 at 42). Gao was one of two individuals who commenced this action, see Compl. (docket no. 1), but Gao did not thereafter seek appointment as a lead plaintiff, see Order (docket no. 60). According to a certification filed with the original complaint, Gao purchased and another 100 shares of Athira stock on March 25, 2021, at the price of $17.00 per share. See Pl.’s Certif. (docket no. 1-1 at 3); see also Am. Compl. at ¶ 90 (docket no. 74).

Thus, Gao has both Securities Act Claims and Exchange Act Claims, but unlike Nacif and Rafi, Gao is not bound by the decision not to replead the Exchange Act Claims and does not have interests that are antagonistic toward or in conflict with those of absent putative class members. The Court treats the pending motion as seeking leave to amend to join Gao as a named plaintiff and hereby GRANTS the request. B. Allocation

The parties propose to settle both the Securities Act Claims and the Exchange Act Claims on the following terms. Defendants would deposit the gross settlement amount of $10 million into an interest-bearing escrow account. Attorney’s fees (predicted to be 33⅓% of the gross amount), litigation costs (capped at $205,000), awards to the named plaintiffs (no more than $30,000), settlement administration fees (estimated to be

$200,000), taxes (approximately $200,000), and escrow account fees1 would be deducted before the remaining net settlement proceeds (roughly $6-to-6.5 million, depending on interest rates and the Court’s rulings on requests for attorney’s fees, etc.) would be distributed to class members. The method for calculating the amount due to each class member, denominated by the parties as the “Plan of Allocation,” is not a provision of the

Free access — add to your briefcase to read the full text and ask questions with AI

Nacif v. Athira Pharma Inc, (W.D. Wash. 2024).

Nacif v. Athira Pharma Inc (Nacif v. Athira Pharma Inc) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related